Volume 3, Issue 6, December 2017, Page: 77-85
Naproxen-Gelucire Nanoformulations for Improved Solubility and Dissolution Rate of Poorly Water-Soluble Drug Naproxen
Sandeep Patnaik, Andhra Pradesh Medtech Zone, Vishakhapatnam, India
Aditya Dileep Kurdekar, Laboratories for Nanoscience and Nanotechnology Research, Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthinilayam, India
Lakshmi Adinarayana Avinash Chunduri, Andhra Pradesh Medtech Zone, Vishakhapatnam, India
Chinnakoti Prathibha, Laboratories for Nanoscience and Nanotechnology Research, Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthinilayam, India
Kamisetti Venkataramaniah, Laboratories for Nanoscience and Nanotechnology Research, Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthinilayam, India
Received: Jun. 23, 2017;       Accepted: Oct. 25, 2017;       Published: Nov. 23, 2017
DOI: 10.11648/j.jddmc.20170306.11      View  1834      Downloads  111
Abstract
Naproxen-Gelucire Nanoformulations (NFs) in terms of their phase solubility behavior, physico-chemical characteristics, cytotoxicity and morphology and dissolution enhancement has been studied using the poorly water soluble drug, naproxen. The NFs were prepared via wet milling using a conventional Retsch Planetary ball mill in various ratios of drug to polymer (1:1, 1:2, 1:3, 1:4). The release rate of naproxen from various ratios of drug/polymer nanoparticles was investigated using USP paddle apparatus (type II). A comparative phase solubility of naproxen was performed in different carrier concentrations of simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8). The highest dissolution enhancement was achieved for the formulation with ratio of 1:4. This is a 160% enhancement when compared to that of the pure drug. The ability of amphiphillic surfactant carriers to accelerate in vitro dissolution of poorly water-soluble drugs has been attributed to wetting, micellar solubilization, and/or deflocculation. The Korsemeyer–Peppas model most aptly fits the in vitro dissolution data and gives an insight into the possible drug release mechanisms predominated by anamolous non-Fickian diffusion. Thus, the nanoformulations studied can help improve the physicochemical characteristics of naproxen towards its dissolution enhancement and possibly will increase the oral bioavailability of the drug without any adverse cytotoxic consequences.
Keywords
Naproxen, Gelucire, Nanoformulations, Solubility, Dissolution, Bioavalability
To cite this article
Sandeep Patnaik, Aditya Dileep Kurdekar, Lakshmi Adinarayana Avinash Chunduri, Chinnakoti Prathibha, Kamisetti Venkataramaniah, Naproxen-Gelucire Nanoformulations for Improved Solubility and Dissolution Rate of Poorly Water-Soluble Drug Naproxen, Journal of Drug Design and Medicinal Chemistry. Vol. 3, No. 6, 2017, pp. 77-85. doi: 10.11648/j.jddmc.20170306.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Harrington P. J. & Lodewijk, E. (1997) Twenty, Years of Naproxen Technology. Org. Process Res. Dev. 1, 72–76.
[2]
Global and Chinese Naproxen (CAS22204-53-1) Industry-2015 http://www.researchandmarkets.com/reports/3343235/ Global.
[3]
Mura, P., Faucci, M. T., Manderioli, a, Bramanti, G. & Parrini, P. (1999), Thermal behavior and dissolution properties of naproxen from binary and ternary solid dispersions. Drug Dev. Ind. Pharm. 25, 257–64.
[4]
Mura, P., Faucci, M. T. & Bettinetti, G. P. (2001), The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-??-cyclodextrin. Eur. J. Pharm. Sci. 13, 187–194.
[5]
Mura, P. et al. (2005) Interaction of naproxen with ionic cyclodextrins in aqueous solution and in the solid state. J. Pharm. Biomed. Anal. 37, 987–994.
[6]
Mura, P. et al (2005) Solid-state characterization and dissolution properties of Naproxen-Arginine-Hydroxypropyl-cyclodextrin ternary system. Eur. J. Pharm. Biopharm. 59, 99–106.
[7]
Tiong, N. & Elkordy, A. A. (2009), Effects of liquisolid formulations on dissolution of naproxen. Eur. J. Pharm. Biopharm. 73, 373–384.
[8]
Lee, B. J. & Lee, J. R. (1995) Enhancement of solubility and dissolution rate of poorly water- soluble naproxen by complexation with 2-hydroxypropyl-beta- cyclodextrin. Arch. Pharm. Res. 18, 22–26.
[9]
Allesø, M. et al. (2009) Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J. Control. Release 136, 45–53.
[10]
Bogdanova, S., Pajeva, I., Nikolova, P., Tsakovska, I. & Müller, B. (2005) Interactions of poly(vinylpyrrolidone) with ibuprofen and naproxen: experimental and modeling studies. Pharm. Res., 22, 806–15.
[11]
Javadzadeh, Y. et al. (2010) Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. Colloids Surf. B. Biointerfaces 81, 498–502.
[12]
Liversidge, G. G. & Conzentino, P. 1(995) Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125, 309–313.
[13]
Müller, R. H., Jacobs, C. & Kayser, O. (2001) Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3–19.
[14]
Patravale, V. B., Date, A. a & Kulkarni, R. M.(2004) Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56, 827–40.
[15]
Bhakay, A., Merwade, M., Bilgili, E. & Dave, R. N.(2011) Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev. Ind. Pharm. 37, 963–976.
[16]
George, M. & Ghosh, I. (2013) Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. Eur. J. Pharm. Sci. 48, 142–152.
[17]
Ghosh, I. & Michniak-Kohn, B.(2012) Design and characterization of submicron formulation for a poorly soluble drug: The effect of Vitamin e TPGS and other solubilizers on skin permeability enhancement. Int. J. Pharm. 434, 90–98.
[18]
Reintjes, T.(2011) Solubility Enhancement with BASF Pharma Polymers Solubilizer Compendium. October.
[19]
Patnaik, S., Aditha, S. K., Rattan, T. & Kamisetti, V.(2015) Aceclofenac-Soluplus Nanocomposites for Increased Bioavailability. Soft Nanosci. Lett. 5, 13–20.
[20]
Noyes A. A, Whitney W. R. (1897) The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19: 930-934.
[21]
Florez-Zamora, M. I. et al. (2008) Comparative study of Al-Ni-Mo alloys obtained by mechanical alloying in different ball mills. Rev. Adv. Mater. Sci. 18, 301–304.
[22]
Ahuja, N., Katare, O. P. & Singh, B.(2007) Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur. J. Pharm. Biopharm. 65, 26–38.
[23]
Maulvi, F. a. et al. (2007) Improvement of dissolution rate of aceclofenac by solid dispersion technique. Powder Technol. 207, 218–226.
[24]
Higuchi, T. & Connors, K. A. (1965) Phase-Solubility Techniques. Adv. Anal. Chem. Instrum. 4, 117–210 (1965).
[25]
Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P. & Peppas, N. A. (1983) Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 15, 25–35.
Browse journals by subject